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Pseudomonas aeruginosa is an opportunistic extracellular
pathogen for debilitated or immuno-compromised
patients, capable of forming biofilms on the epithelial
surfaces of various tissues in such patients. The biofilm
formation allows the pathogen to evade antibiotic therapy
or immune attack, ensuring its long term residence and a
n i c h ei nt h eb o d y .A n ys u b s e q u e n ta t t a c kb ya ni n t e r n a l
or external invader such as cancers, viruses or parasites
can threaten and cause the resident bacteria to lose their
sanctuary. Consequently, P. aeruginosa appears to pro-
duce protein weapons, such as azurin, that has structural
similarity to immunoglobulins and that can preferentially
enter to cancer cells and bind many important intracellu-
lar or extracellular proteins, including signalling proteins,
that are important for cancer growth. Such binding
results in the interference of multiple pathways by which
cancer cells grow, significantly inhibiting their growth
both in vitro and in vivo in live mice. Azurin can also
prevent precancerous lesion formation in normal mouse
mammary cells, when such cells are exposed to a carci-
nogen such as 7,12- dimethyl-benz-antracene, thus
demonstrating cancer preventive activity, resembling a
vaccine. In addition to its anticancer activity, azurin
interferes in the growth of viruses such as HIV/AIDS and
parasites such as the malarial parasite Plasmodium falci-
parum or the toxoplasmosis- causing parasite Toxo-
plasma gondii. Not only azurin, but some of the peptides
derived from azurin such as P28, comprising of 28 azurin
amino acid residues 50 to 77, demonstrate entry specifi-
city in cancer cells and significant cytotoxicity including
inhibition of angiogenesis. P28 is currently undergoing
phase I human clinical trials in the Unites States with
early encouraging results. The ability of azurin to
interfere in multiple pathways by which cancer cells grow
or interfere in the growth of HIV/AIDS virus or malarial,
taxoplasmosis parasites distinguishes it from rationally
designed anticancer drugs of the pharmaceutical industry
which inhibit a single or a limited number of validated
targets in the growth progression pathways of the cancer
cells. The cancer cells respond to such rationally
designed drugs by changing or switching off the target,
thereby rapidly becoming drug resistant. It remains to be
seen if azurin will demonstrate efficacy in human patients
suffering from multiple diverse diseases such as cancers,
HIV/AIDS and malaria, and if effective, may exhibit
much less susceptibility to resistance development by the
disease agents.
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